Purple Innovation executed a new five-year $100 million senior secured credit facility, consisting of a $45 million term loan and a $55 million revolving line of credit, with a group of financial institutions led by KeyBanc Capital Markets.
Selecta Biosciences entered into a debt financing facility for up to $35 million with Oxford Finance and Silicon Valley Bank. Selecta will use the financing to retire $12.6 million of existing debt, to advance its ImmTOR pipeline and for business development activities.
FireMon secured a debt financing of $40 million from Silicon Valley Bank. FireMon, which experienced more than 300% sequential growth in Q2/20 compared with Q1/20, will use the additional funding to accelerate sales momentum and product innovation.
Silicon Valley Bank (SVB) and Investec Bank closed $265 million in credit facilities for Sunrun. Silicon Valley Bank acted as the administrative agent and both Silicon Valley Bank and Investec were coordinating lead arrangers.
Silicon Valley Bank is providing an up to $15 million asset-based revolving line of credit to Kerecis to support the company’s near-term working capital needs. In addition, Kerecis’ leading investors and other lenders provided the company with $6 million in loans that largely consist of convertible notes. The funding will be used to support the […]
Silicon Valley Bank provided a $15 million credit facility to Nasuni as part of a combined $40 million financing package that also included $25 million in new equity financing.
Silicon Valley Bank replaced HTG Molecular Diagnostics’ existing senior credit facility with a $10 million senior term loan agreement.
BofA Securities, BBVA Securities and PNC Capital Markets acted as joint lead arrangers and joint bookrunners on a three-year, $670 million secured credit facility for Diodes Incorporated.
JPMorgan Chase Bank and Silicon Valley Bank served as joint bookrunners and joint lead arrangers on a $150 million five-year secured revolving credit facility to Beyond Meat.
Aclaris Therapeutics, a physician-led biopharmaceutical company, entered into a loan and security agreement with Silicon Valley Bank pursuant to which Aclaris has borrowed $11.0 million.